Literature DB >> 12901837

PML nuclear bodies and neuronal intranuclear inclusion in polyglutamine diseases.

Junko Takahashi1, Hiroto Fujigasaki, Kiyoshi Iwabuchi, Amalia C Bruni, Toshiki Uchihara, Khalid H El Hachimi, Giovanni Stevanin, Alexandra Dürr, Anne Sophie Lebre, Yvon Trottier, Hugues de Thé, Junichi Tanaka, Jean Jacques Hauw, Charles Duyckaerts, Alexis Brice.   

Abstract

In polyglutamine diseases, accumulation in the nucleus of mutant proteins induces the formation of neuronal intranuclear inclusions (NIIs). The nucleus is compartmentalized into structural and functional domains, which are involved in NII formation. Promyelocytic leukemia protein (PML), a major component of nuclear bodies, and mSin3A, a component of the transcription co-repressor complex, were used to investigate how the intranuclear domains/sites relate to NII formation in SCA2, SCA3, SCA7, SCA17 and DRPLA brains. We demonstrate that the size of PML-positive intranuclear structures was larger in pathological brains than in control ones and that these structures contained mutant proteins. PML colocalized only with small NIIs, which maintained the ring-like structure of normal nuclear bodies. Enlarged ring-like PML-positive structures, devoid of mutant proteins, were also found and might represent structures where mutant polyglutamine proteins have been successfully processed. These data suggest that NIIs originate from nuclear bodies, where mutant proteins accumulate for degradation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901837     DOI: 10.1016/s0969-9961(03)00080-9

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  16 in total

Review 1.  PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Nucleus       Date:  2014       Impact factor: 4.197

2.  Ubiquitin-Modulated Phase Separation of Shuttle Proteins: Does Condensate Formation Promote Protein Degradation?

Authors:  Thuy P Dao; Carlos A Castañeda
Journal:  Bioessays       Date:  2020-09-03       Impact factor: 4.345

Review 3.  The role of PML in the nervous system.

Authors:  Paolo Salomoni; Joanne Betts-Henderson
Journal:  Mol Neurobiol       Date:  2010-12-15       Impact factor: 5.590

4.  Neuronal intranuclear inclusion disease without polyglutamine inclusions in a child.

Authors:  Kathryn McFadden; Ronald L Hamilton; Sam J Insalaco; Lawrence Lavine; Majeed Al-Mateen; Guoji Wang; Clayton A Wiley
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

Review 5.  Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7.

Authors:  Anna Niewiadomska-Cimicka; Yvon Trottier
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

6.  A cellular system that degrades misfolded proteins and protects against neurodegeneration.

Authors:  Lili Guo; Benoit I Giasson; Alex Glavis-Bloom; Michael D Brewer; James Shorter; Aaron D Gitler; Xiaolu Yang
Journal:  Mol Cell       Date:  2014-05-29       Impact factor: 17.970

7.  Calpain 5 is highly expressed in the central nervous system (CNS), carries dual nuclear localization signals, and is associated with nuclear promyelocytic leukemia protein bodies.

Authors:  Ranjana Singh; M Kathryn Brewer; Charles B Mashburn; Dingyuan Lou; Vimala Bondada; Brantley Graham; James W Geddes
Journal:  J Biol Chem       Date:  2014-05-16       Impact factor: 5.157

8.  Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus.

Authors:  Mike Reichelt; Li Wang; Marvin Sommer; John Perrino; Adel M Nour; Nandini Sen; Armin Baiker; Leigh Zerboni; Ann M Arvin
Journal:  PLoS Pathog       Date:  2011-02-03       Impact factor: 6.823

Review 9.  Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease.

Authors:  Yukiko Shishido-Hara
Journal:  Acta Neuropathol       Date:  2010-05-13       Impact factor: 17.088

10.  Ataxin-1 fusion partners alter polyQ lethality and aggregation.

Authors:  Tina Rich; Archana Varadaraj
Journal:  PLoS One       Date:  2007-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.